Navigation Links
Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients
Date:12/7/2008

(60 percent) and nausea (52 percent).

-- There were no reports of deep-vein thrombosis or pulmonary embolism.

-- As initial therapy, all patients had a partial response or better, with 36% of patients achieveing a CR.

"We are committed to advancing multiple myeloma treatment that delivers the best patient outcomes," said Nancy Simonian, M.D., Chief Medical Officer, Millennium. "The tolerability of this novel four-drug combination allows us to study its efficacy relative to two of the most active three-drug regimens for previously untreated multiple myeloma patients."

During Phase I, patients received VELCADE at 1.3 mg/m(2) on days 1, 4, 8 and 11 on a 21-day cycle for up to eight cycles; dexamethasone at 40 mg on days 1, 8 and 15; lenalidomide at 15 mg on days 1 through 14; and cyclophosphamide at 100, 200, 300, 400 or 500 mg/m(2) on days 1 and 8 for up to eight 21-day cycles. This was followed by VELCADE at 1.3 mg/m(2) on days 1, 8, 15 and 22 for four 42-day maintenance cycles. The primary endpoint of this Phase I trial was the determination of the maximum tolerated dose of cyclophosphamide in combination with VcDR. The primary endpoints of the ongoing Phase II portion of the trial are complete response and very good partial response rates, while the secondary endpoints include progression-free survival, overall survival, safety and tolerability.

About Multiple Myeloma

Multiple myeloma is the second most common hematologic malignancy and although the disease is predominantly a cancer of the elderly (the median age of onset is 70 years), recent statistics indicate both increasing incidence and younger age of onset. In the U.S., more than 50,000 individuals have MM and 20,000 new cases are diagnosed each year. Worldwide there are approximately 74,000 new cases and over 45,000 deaths annually.

About VELCADE

VELCADE is co-developed by Mi
'/>"/>

SOURCE Millennium: The Takeda Oncology Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... 14, 2014  Invivotek L.L.C., a member of ... announce that its animal research facility was awarded ... and Accreditation of Laboratory Animal Care International (AAALAC). ... science worldwide through voluntary accreditation and assessment programs. ... and use in 38 countries. Invivotek ...
(Date:7/14/2014)... , July 14, 2014  Remedy Informatics, the ... healthcare delivery and life sciences research, announced that ... Foundation (NPF) to build the first-ever national patient ... cancer and pancreatitis. "The National Pancreas ... change that thoughtful and committed organizations can effect ...
(Date:7/14/2014)... SAN DIEGO , July 14, 2014  More than ... love their smartphones and tablet computers -- but their eyes ... humans have never needed before, and the eye has not ... lives and what our eyes can do comfortably often results ... symptoms collectively known as Digital Eye Strain. Now ZEISS has ...
Breaking Medicine Technology:Invivotek Awarded Full AAALAC Accreditation for Excellence in Laboratory Animal Care and Use 2Remedy Informatics Partners with National Pancreas Foundation to Build a National Patient Registry 2Remedy Informatics Partners with National Pancreas Foundation to Build a National Patient Registry 3New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 2New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 3
... VOLC ), a leading developer and manufacturer of ... and treatment of coronary and peripheral vascular disease, today announced ... quarter of fiscal 2011 on Wednesday, May 4. ... financial results and operating activities open to all interested parties ...
... 25, 2011 STAAR Surgical Company (NASDAQ: ... minimally invasive ophthalmic lenses for refractive surgery, today announced ... (ICL™) V4c design.  The V4c design incorporates a proprietary ... a size determined to optimize the flow of fluid ...
Cached Medicine Technology:Volcano Corporation Schedules First Quarter Conference Call, Webcast 2Visian® ICL and Toric ICL V4c Receive CE Mark Approval 2Visian® ICL and Toric ICL V4c Receive CE Mark Approval 3Visian® ICL and Toric ICL V4c Receive CE Mark Approval 4
(Date:7/14/2014)... (PRWEB) July 14, 2014 ... Ultra performance liquid chromatography or UPLC is ... of liquid chromatography that involves the use ... conditions to separate chromatographic compounds. This highly ... faster detection and analysis of chromatography samples. ...
(Date:7/14/2014)... July 14, 2014 Skin ... its Grand Opening on Monday, July 14th, located ... The celebration will last all week through Saturday, ... patients. Everyone is welcomed to attend. The business ... provides physician-administered skincare, anti-aging, weight loss services, and ...
(Date:7/14/2014)... 2014 KeyPoint Credit Union is teaming ... 5K run and one-mile family fun walk. The run ... attractions, and finishes inside Levi’s® Stadium. , Over the ... for the Mission City Community Fund. All proceeds benefit ... , Seasoned athletes, part-time pavement-pounders and walkers are invited ...
(Date:7/14/2014)... July 14, 2014 T.E.N., an ... firm, announced today that nominations will be accepted ... Information Security Executive® (ISE®) North America Awards. ... the Year, which recognizes executives who have made ... management, data-asset protection, regulatory compliance, privacy and information ...
(Date:7/14/2014)... 14, 2014 Many people are unhappy ... plastic surgery to reduce a “double chin.” A ... the need to go under the knife. Jawflex is ... jaw muscles, therefore tightening the skin in that area ... Jawflex is used for facial exercise, double chin elimination ...
Breaking Medicine News(10 mins):Health News:Need for Faster Sample Analysis Drives Demand for UPLC, According to New Trend Report Published by Global Industry Analysts, Inc. 2Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 2Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 3Health News:T.E.N. Accepting Nominations for the 2014 Information Security Executive® North America Awards 2Health News:T.E.N. Accepting Nominations for the 2014 Information Security Executive® North America Awards 3Health News:Jawflex | Double Chin Exercise for Double Chin Reduction 2
... Medical Center have uncovered a protein in nerve cells that ... manufacture drugs that are capable of blocking chronic pain, by ... alleviating chronic pain have focused on the "second order" neurons ... brain. It's difficult to inhibit the activity of these neurons ...
... and Social Welfare’s Health Education Unit (HEU) in Swaziland ... than 40 communities in the country. // ... get the people thinking abut HIV AIDS through documentaries. ... Public Relations Officer Nana Mdluli said the campaign would ...
... the investigators at St. Jude Children's Research Hospital it was ... gland function during nursing can also initiate leukemias. // ... and fuses with another gene. The discovery of the normal ... the activity of its mutated form might be used in ...
... age 45 years or older who experience migraines with ... are at a higher risk for heart// attack, ischemic ... compared to women who do not report a migraine ... form of migraine, was not associated with increased risk ...
... at Buffalo researchers are conducting one of the ... ,The project is expected to provide ... quality is critical, such as in health-care facilities ... guest rooms in the Buffalo Niagara Marriott in ...
... China on Saturday reported a new outbreak of bird flu ... Xinjiang.// ,The national avian influenza laboratory tested samples ... stemming from an outbreak that began on July 14 near ... ,A total of 3,045 chickens died in the outbreak, and ...
Cached Medicine News:Health News:It may be possible to switch off acute pain 2Health News:Gene Responsible For Mammary Gland Function, When Mutated Results in Leukemias 2Health News:Gene Responsible For Mammary Gland Function, When Mutated Results in Leukemias 3Health News:Migraines with Aura Associated with Increased Risk for Cardiovascular Disease 2Health News:Scientists Put "Allergy-Friendly" Hotel Rooms to the Test 2Health News:Scientists Put "Allergy-Friendly" Hotel Rooms to the Test 3
Stryker's 40-liter insufflator provides superior performance with unprecedented safety and reliability....
Bipolar forceps...
... visualize the presence of Human Papilloma Virus (HPV)., ... sample types: tissue, monolayer-based preparations, and conventional Pap. ... The Family 16 probe cocktail has an affinity ... 39, 51, 52, 56, 58, and 66. The ...
... Common primary human fungal pathogens ... spp., opportunistic fungal pathogens, including ... cerevisiae, Acremonium, Coccidioides immitis, Histoplasma ... and Pneumocystis carinii. The (1-3)--D-glucan ...
Medicine Products: